|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
CA3001131A1
(en)
|
2015-11-02 |
2017-05-11 |
Five Prime Therapeutics, Inc. |
Cd80 extracellular domain polypeptides and their use in cancer treatment
|
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
US20190033322A1
(en)
*
|
2016-02-03 |
2019-01-31 |
The Cleveland Clinic Foundation |
Detection and treatment of il-17 and il-13 related conditions
|
|
EP3440219B1
(en)
*
|
2016-04-08 |
2021-09-01 |
Centre National De La Recherche Scientifique |
Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatment
|
|
WO2018027524A1
(en)
*
|
2016-08-09 |
2018-02-15 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibody formulation
|
|
WO2018075740A1
(en)
*
|
2016-10-21 |
2018-04-26 |
Merck Sharp & Dohme Corp. |
Treating cancer with a combination of pd-1 antagonist and an il-27 antagonist
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
CN110546509A
(zh)
|
2017-04-28 |
2019-12-06 |
戊瑞治疗有限公司 |
用cd80细胞外结构域多肽进行治疗的方法
|
|
US11220550B2
(en)
*
|
2017-05-25 |
2022-01-11 |
Bristol-Myers Squibb Company |
Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
|
|
WO2018236728A1
(en)
|
2017-06-18 |
2018-12-27 |
Kindred Biosciences, Inc. |
ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE
|
|
AU2018318440A1
(en)
|
2017-08-15 |
2020-02-13 |
Kindred Biosciences, Inc. |
IgG Fc variants for veterinary use
|
|
EP3483180A1
(en)
*
|
2017-11-14 |
2019-05-15 |
Affilogic |
Multi specific molecules
|
|
WO2019140150A1
(en)
*
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
WO2019152344A1
(en)
*
|
2018-01-30 |
2019-08-08 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for treating inflammation and cancer
|
|
US20210363590A1
(en)
*
|
2018-05-21 |
2021-11-25 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
|
CN110563842B
(zh)
*
|
2018-06-06 |
2022-07-29 |
浙江博锐生物制药有限公司 |
针对程序性死亡配体(pd-l1)的抗体及其应用
|
|
KR102091637B1
(ko)
*
|
2018-07-10 |
2020-03-20 |
연세대학교 산학협력단 |
면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
|
|
CN109053891B
(zh)
|
2018-09-17 |
2021-12-21 |
苏州泓迅生物科技股份有限公司 |
一种抗pd-l1抗体及其制备方法和应用
|
|
WO2020150208A1
(en)
*
|
2019-01-14 |
2020-07-23 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors
|
|
AU2020224137B2
(en)
|
2019-02-22 |
2026-01-08 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors
|
|
PL3946377T3
(pl)
*
|
2019-04-03 |
2026-04-20 |
Orega Biotech |
Terapie skojarzone oparte na inhibitorach pd1 i il-17b
|
|
WO2020218322A1
(ja)
*
|
2019-04-23 |
2020-10-29 |
国立大学法人東北大学 |
血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測
|
|
MX2021013272A
(es)
|
2019-05-03 |
2021-11-17 |
Five Prime Therapeutics Inc |
Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
|
|
CN115698717A
(zh)
*
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
KR20230017211A
(ko)
*
|
2020-04-30 |
2023-02-03 |
얀센 파마슈티카 엔.브이. |
Il-17 경로의 조절인자를 식별하는 방법
|
|
US20240400668A1
(en)
*
|
2022-07-29 |
2024-12-05 |
Jinfeng Laboratory |
Non-human mammalian model expressing il-8 and use thereof
|
|
EP4735889A1
(en)
*
|
2023-06-30 |
2026-05-06 |
Universität Duisburg-Essen |
Il-17 based therapy
|